U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H31F5N4O
Molecular Weight 522.5533
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GIREDESTRANT

SMILES

C[C@@H]1CC2=C(NC3=C2C=CC=C3)[C@H](N1CC(F)(F)CO)C4=C(F)C=C(NC5CN(CCCF)C5)C=C4F

InChI

InChIKey=GQCXHIKRWBIQMD-AKJBCIBTSA-N
InChI=1S/C27H31F5N4O/c1-16-9-20-19-5-2-3-6-23(19)34-25(20)26(36(16)14-27(31,32)15-37)24-21(29)10-17(11-22(24)30)33-18-12-35(13-18)8-4-7-28/h2-3,5-6,10-11,16,18,26,33-34,37H,4,7-9,12-15H2,1H3/t16-,26-/m1/s1

HIDE SMILES / InChI
Molecular Formula C27H31F5N4O
Molecular Weight 522.5533
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
149124
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
72.8 ng/mL
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
231 ng/mL
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
30 mg 1 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
718 ng/mL
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
90 mg 1 times / day steady-state, oral
dose: 90 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
792 ng/mL
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
1540 ng/mL
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
250 mg 1 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1090 ng × h/L
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
3850 ng × h/L
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
30 mg 1 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
11500 ng × h/L
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
90 mg 1 times / day steady-state, oral
dose: 90 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
13400 ng × h/L
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
25800 ng × h/L
OTHER
https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/oncology/roche-asco-2021/posters/oncology-annual-meeting-2021-poster-jhaveri-safety-and-activity-of-single-agent-giredestrant-GDC-9545-from-a-phase-Iab-study-in-patients.pdf
250 mg 1 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GIREDESTRANT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Substance Class Chemical
Created
by admin
on Tue Apr 01 21:09:21 GMT 2025
Edited
by admin
on Tue Apr 01 21:09:21 GMT 2025
Record UNII
28P3DU6DB3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GDC-9545
Preferred Name English
GIREDESTRANT
USAN   INN  
Official Name English
giredestrant [INN]
Common Name English
GIREDESTRANT [USAN]
Common Name English
(1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)-3-AZETIDINYL)AMINO)PHENYL)-.BETA.,.BETA.-DIFLUORO-1,3,4,9-TETRAHYDRO-3-METHYL-2H-PYRIDO(3,4-B)INDOLE-2-PROPANOL
Systematic Name English
3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO(3,4-B)INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL
Systematic Name English
2H-PYRIDO(3,4-B)INDOLE-2-PROPANOL, 1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)-3-AZETIDINYL)AMINO)PHENYL)-.BETA.,.BETA.-DIFLUORO-1,3,4,9-TETRAHYDRO-3-METHYL-, (1R,3R)-
Systematic Name English
RO-7197597
Code English
Giredestrant [WHO-DD]
Common Name English
RO7197597
Code English
Code System Code Type Description
SMS_ID
300000024131
Created by admin on Tue Apr 01 21:09:21 GMT 2025 , Edited by admin on Tue Apr 01 21:09:21 GMT 2025
PRIMARY
PUBCHEM
121410806
Created by admin on Tue Apr 01 21:09:21 GMT 2025 , Edited by admin on Tue Apr 01 21:09:21 GMT 2025
PRIMARY
FDA UNII
28P3DU6DB3
Created by admin on Tue Apr 01 21:09:21 GMT 2025 , Edited by admin on Tue Apr 01 21:09:21 GMT 2025
PRIMARY
NCI_THESAURUS
C147030
Created by admin on Tue Apr 01 21:09:21 GMT 2025 , Edited by admin on Tue Apr 01 21:09:21 GMT 2025
PRIMARY
USAN
HI-202
Created by admin on Tue Apr 01 21:09:21 GMT 2025 , Edited by admin on Tue Apr 01 21:09:21 GMT 2025
PRIMARY
INN
11226
Created by admin on Tue Apr 01 21:09:21 GMT 2025 , Edited by admin on Tue Apr 01 21:09:21 GMT 2025
PRIMARY
CAS
1953133-47-5
Created by admin on Tue Apr 01 21:09:21 GMT 2025 , Edited by admin on Tue Apr 01 21:09:21 GMT 2025
PRIMARY
Related Record Type Details
ESTROGEN RECEPTOR BETA
TARGET->INHIBITOR, RECEPTOR DEGRADER
IC50
POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY H MEMBER 2
OFF-TARGET->INHIBITOR
IC50
ESTROGEN RECEPTOR
TARGET->INHIBITOR, RECEPTOR DEGRADER
induction of an inactive conformation of the ER ligand-binding domain (LBD) and 2) induces ER? (WT and mutant) degradation.
IC50
Structure of 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO(3,4-B)INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL (2R,3R)-TARTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of GIREDESTRANT
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
log D CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966